FDA announces prazosin recall over nitrosamine concerns
Tap title to read story
The U.S. Food and Drug Administration says more than 580,000 bottles of prazosin hydrochloride have been voluntarily recalled nationwide over possible nitrosamine impurities considered potentially cancer causing. New Jersey-based Teva Pharmaceuticals USA and distributor Amerisource Health Services initiated the recall of multiple capsule strengths earlier this month. The FDA assigned the affected lots a Class II risk, noting that prazosin relaxes blood vessels to lower blood pressure and is sometimes used for PTSD-related nightmares and sleep disturbances.